Publications by authors named "Alex Willing"
Direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection have delivered high response rates (>95%) and simplified the management of HCV treatment, permitting non-specialists to manage patients without advanced liver disease. We collected and reviewed global data on the registration and reimbursement (government subsidised) of HCV therapies, including restrictions on reimbursement. Primary data collection occurred between Nov 15, 2021, and July 24, 2023, through the assistance of a global network of 166 HCV experts.
View Article and Find Full Text PDFArticle Synopsis
- People who inject drugs are heavily impacted by HIV and hepatitis C virus infections, but there is a lack of global data on their testing and treatment coverage, prompting a systematic review to gather this information.
- The review involved searching various databases for studies published between January 2017 and April 2022, focusing on the proportions of people who inject drugs receiving testing and treatment for HIV and HCV across different countries.
- The findings revealed that of the data analyzed, about 48.8% of people who inject drugs were recently tested for HIV antibodies and 47.1% had ever been tested for HCV antibodies, with some countries showing notably high testing coverage.
Article Synopsis
- The study conducted a global systematic review to assess the prevalence of injecting drug use (IDU) and its associated harms, including infections like HIV and hepatitis, as well as overdose.
- Researchers analyzed a vast number of reports published from 2017 to 2022 to gather data on socio-demographic characteristics, risk exposures, and health outcomes related to IDU.
- The findings revealed that 14.8 million individuals aged 15-64 worldwide inject drugs, with a notable gender disparity in the prevalence of IDU, as well as unique risks faced by women and transgender individuals.